ISN 2019 – Kidney benefit could help Invokana compete again
Johnson & Johnson’s Invokana has fallen behind SGLT2 rivals over amputation fears, but success in the Credence renal trial, profiled at the International Society of…
EASL 2019 – Research reminds hep B bulls that progress will be slow
Presentations from Assembly Biosciences and Spring Bank Pharmaceuticals could disappoint those hoping to see more definitive steps towards a functional cure for hepatitis…
EASL 2019 – Alnylam lays out givosiran's benefit
Full data from Alnylam's pivotal givosiran programme show a big impact for severe patients, though a case still needs to be made for a broader population.
EASL 2019 – Intercept and medics clash in Nash
Yesterday’s high-profile presentation of the Regenerate trial failed to quash concerns about Ocaliva in Nash, despite Intercept’s best attempts to polish the data.
EASL 2019 – Having filed to float, all Cirius needs now is the data
The IPO hopeful Cirius Therapeutics presented intriguing Nash data at EASL, but with the final readout from a phase IIb study looming the company’s real value is hard to…
EASL 2019 – Novo buys into Gilead’s Nash combo plan
Today’s deal will see the companies take a triple combination into clinical trials.
Upcoming events – a legal verdict for Enbrel and a clinical one for Cymabay
Amgen awaits a make-or-break US verdict on its best-selling drug, while Cymabay looks for evidence that it could become a Nash contender.
EASL 2019 – Intercept builds a case for Ocaliva
A look at the abstract on Intercept’s Regenerate trial seems to confirm the earlier topline result, ahead of a full data presentation later today.
EASL 2019 – Viking to push the limits of its Nash contender
Encouraging results from Viking Therapeutics’ lead Nash project have prompted the company to ask how low it can go.
Kickstarting ideas
Independent, data-driven daily news and analysis on pharma, biotech and medtech.